Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032663 | 0.90 | NR1H4 (0.51) | NR1H4HTTDAGLAHSD11B1GAA | |
| SCHEMBL5124229 | 0.83 | GAA (0.48) | NR1H4HTTDAGLAGAA | |
| SCHEMBL5114179 | 0.76 | PSEN1 (0.44) | NR1H4HTTDAGLAGAA | |
| SCHEMBL4036166 | 0.76 | HTT (0.49) | NR1H4HTTHSD11B1LMNAPKM | |
| SCHEMBL4032633 | 0.76 | HTT (0.48) | NR1H4HTTDAGLAGAALMNA | |
| SCHEMBL6188678 | 0.72 | HTT (0.51) | NR1H4HTTDAGLAGAA | |
| SCHEMBL5803141 | 0.72 | VCAM1 (0.39) | NR1H4HTTDAGLAGAALMNA | |
| SCHEMBL5115197 | 0.72 | MCOLN3 (0.51) | HTTHSD11B1GAA | |
| SCHEMBL5117215 | 0.71 | HTT (0.56) | HTTHSD11B1GAA | |
| SCHEMBL22467327 | 0.71 | TP53 (0.39) | NR1H4HTTHSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | NR1H4 15/4885HTT 2903/4885DAGLA 3321/4885 |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | DHPS, DPYD, TYMP | NR1H4 4176/4885HTT 3709/4885DAGLA 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.